The improvement in scanners is a great addition to cancer detection, especially for those with cancers near term who are able to access these machines.
However, with focusing on the scanner improvement only, then aren't we overlooking the key advantage in the uptake of the bisPSMA product and what this means side by side potentially with existing products going forward i.e. potentially better imaging all round regardless of scanner (better scanner even better imaging) due to better uptake?
That partnering with the ability to deliver therapies via bisPSMA knowing it has already been taken up from imaging.
CU6 Price at posting:
$4.05 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)